MetLife Investment Advisors LLC lifted its position in Quidel Co. (NASDAQ:QDEL) by 8.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 15,132 shares of the company’s stock after acquiring an additional 1,229 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Quidel were worth $1,006,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of QDEL. NewSquare Capital LLC bought a new stake in shares of Quidel in the 2nd quarter worth $178,000. Great West Life Assurance Co. Can grew its stake in shares of Quidel by 55.8% in the 2nd quarter. Great West Life Assurance Co. Can now owns 3,405 shares of the company’s stock worth $227,000 after acquiring an additional 1,220 shares in the last quarter. Winslow Evans & Crocker Inc. bought a new stake in shares of Quidel in the 2nd quarter worth $236,000. Xact Kapitalforvaltning AB bought a new stake in shares of Quidel in the 1st quarter worth $241,000. Finally, Castle Rock Wealth Management LLC bought a new position in Quidel during the second quarter valued at about $327,000. Hedge funds and other institutional investors own 88.44% of the company’s stock.

Several equities analysts recently weighed in on the stock. Piper Jaffray Companies restated an “overweight” rating and set a $74.00 price target on shares of Quidel in a research report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Quidel from a “hold” rating to a “strong-buy” rating and set a $80.00 price target for the company in a research report on Tuesday, August 14th. Craig Hallum increased their price target on shares of Quidel from $64.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. ValuEngine lowered shares of Quidel from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 19th. Finally, Barclays increased their price target on shares of Quidel from $65.00 to $78.00 and gave the company an “overweight” rating in a research report on Monday, August 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $70.14.

In other Quidel news, SVP Robert Joseph Bujarski sold 38,550 shares of the company’s stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $70.15, for a total transaction of $2,704,282.50. Following the sale, the senior vice president now directly owns 26,153 shares of the company’s stock, valued at $1,834,632.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Douglas C. Bryant sold 12,000 shares of the company’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $65.84, for a total transaction of $790,080.00. Following the sale, the chief executive officer now directly owns 306,313 shares in the company, valued at $20,167,647.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 201,200 shares of company stock worth $13,910,738. Insiders own 16.70% of the company’s stock.

QDEL opened at $63.10 on Thursday. The stock has a market cap of $2.51 billion, a P/E ratio of -901.43, a P/E/G ratio of 1.02 and a beta of 0.98. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.10 and a quick ratio of 0.71. Quidel Co. has a fifty-two week low of $33.01 and a fifty-two week high of $77.63.

Quidel (NASDAQ:QDEL) last posted its quarterly earnings results on Tuesday, August 7th. The company reported $0.36 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.12. The company had revenue of $103.16 million during the quarter, compared to analyst estimates of $102.15 million. Quidel had a net margin of 4.63% and a return on equity of 19.39%. analysts predict that Quidel Co. will post 2.51 earnings per share for the current year.

Quidel Company Profile

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

See Also: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quidel Co. (NASDAQ:QDEL).

Institutional Ownership by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.